International Collaborations

  • T-Cell 2.0 – observational international registry of patients with newly diagnosed peripheral T-cell lymphoma.
  • Global NLPHL One Working Group (GLOW) Initiative
  • Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Current Projects

  • Effect of substitution of platinum chemotherapy in adults with relapsed or refractory non-Hodgkin lymphoma in routine clinical practice (recruiting)
  • Exploring care pathways and developing predictive models for B-cell non-Hodgkin lymphomas outcomes in Australia
  • Gastrointestinal involvement and bowel perforation in lymphoma – prevalence and management in Australia
  • High risk diffuse large B-cell lymphoma in younger patients: treatment patterns and outcomes
  • Obesity prevalence and clinical associations in Australian lymphoma patients
  • Treatment outcomes in treatment-naive and relapsed and refractory T cell/histiocyte rich large B cell lymphoma with a focus on outcomes following novel approaches
  • Real-world outcomes of relapsed and refractory peripheral T cell lymphoma with novel therapeutic agents: A multicentre international registry analysis led by the Australian and New Zealand Lymphoma and Related Diseases Registry (LaRDR)
  • RT Inhibitor Study – Influence of anti-retroviral prophylaxis on outcomes after R-CHOP chemotherapy in DLBCL

Completed Projects

  • Adolescent and young adult, Waldenström macroglobulinemia, testicular lymphoma projects
  • A review of the patterns of treatment and survival outcomes for patients with large B-cell lymphoma in Australia
  • Characteristics of Hodgkin lymphoma in Australia
  • Chronic Lymphocytic Leukaemia data analysis (Scholarly Intensive Placement for Medical Students)
  • Front-line treatment of elderly patients with classical Hodgkin lymphoma: a multicentre retrospective analysis from the ALA and LaRDR
  • GELF criteria project
  • Melbourne Genomics Health Alliance Lymphoma Flagship
  • Movember cancer registries platform
  • Ibrutinib follow-up named patient program (NPP) analyses for CLL and MCL
  • WhiMSICAL – Waldenstrӧm Macroglobulinaemia Study Involving Cart-wheeL
  • Immunoglobulin use and outcomes in Chronic lymphocytic leukaemia And Non-Hodgkin lymphoma – The ICAN Study
  • Long-term outcomes in patients with SMZL treated in the Rituximab Era
  • Real-world Experience of Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B Cell Lymphoma


The Australasian Lymphoma Alliance (ALA)

The ALA has been in a long-term research partnership with the LaRDR. We value our collaboration with the ALA.

GLOW: Global nLPHL One Working GROUP

GLOW is a current LaRDR partner looking to collect data on nodular lymphocyte-predominant Hodgkin lymphoma.

HoLISTIC: Hodgkin Lymphoma International Study for Individual Care

HoLISTIC is a current LaRDR partner looking to optimise the clinical care of Hodgkin lymphoma patients.

T-cell Project 2.0

The T-cell Project 2.0 is a current LaRDR partner looking to improve understanding of Peripheral T-cell lymphoma.












De-identified registry data may be requested by completing a project proposal and data access form and be accompanied by relevant ethics committee certification. Investigators who intend to publish their work but with limited financial resources could contact the registry manager for a publication cost support form. The application will be considered on a case-by-case basis.

Requests from contributing clinicians, staff and academic organisations will be fulfilled without charge.  External requests will be considered by the LaRDR and may incur a fee.

For questions please contact us at